Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Supriadi Gandamihardja"'
Autor:
Unedo Hence Markus Sihombing, Andrijono Andrijono, Gatot Purwoto, Supriadi Gandamihardja, Alida R. Harahap, Primariadewi Rustamadji, Aria Kekalih, Retno Widyawati, Dzicky Rifqi Fuady
Publikováno v:
Journal of the Egyptian National Cancer Institute, Vol 34, Iss 1, Pp 1-9 (2022)
Abstract Background The conventional standard treatment for ovarian cancer is not very effective, and the disease is fatal for women. Cancer Stem Cells (CSCs) that express CD44+/CD24- can contribute to chemoresistance and a poor prognosis. We seek to
Externí odkaz:
https://doaj.org/article/95eb48f1add6407799bae8d73088b8a2
Autor:
Unedo Hence Markus Sihombing, Andrijono, Gatot Purwoto, Supriadi Gandamihardja, Alida R. Harahap, Primariadewi Rustamadji, Aria Kekalih, Retno Widyawati, Dzicky Rifqi Fuady
Publikováno v:
Gynecologic Oncology Reports, Vol 42, Iss , Pp 101005- (2022)
Backgrounds: Ovarian cancer is the 8th deadliest common cancer in women around the world. Almost all ovarian cancer patients would experience chemoresistance, recurrence, and poor prognosis after cytoreductive surgery and platinum-based chemotherapy.
Externí odkaz:
https://doaj.org/article/1f08aeff8d154221869a77dda933f830
Publikováno v:
Majalah Kedokteran Bandung, Vol 46, Iss 4, Pp 247-252 (2014)
The incidence of trophoblastic diseases in Indonesia and developing countries is relatively high compared to the developed countries. The incidence of gestational trophoblast tumors (GTT) after the evacuation of a hydatidiform mole ranges from 10% to
Externí odkaz:
https://doaj.org/article/5b8a8531fc844b7ab06e3f3bb1d3ad6e
Autor:
Supriadi Gandamihardja, Firman F. Wirakusumah, Nurhalim Shahib, Herri S. Sastramihardja, M. Farid Aziz
Publikováno v:
Majalah Kedokteran Bandung, Vol 42, Iss 4, Pp 169-174 (2010)
Cyclooxygenase-2 (COX-2) expression and selective COX-2 inhibitor such as celecoxib, which widely used as antiinflamatory drug, is known to have role in cancer by reducing proliferation and growth of tumor cells, and increasing apoptosis. The researc
Externí odkaz:
https://doaj.org/article/ea05ba8460fc40b493108d5b38631f3b
Autor:
Unedo Hence Markus Sihombing, Andrijono Andrijono, Gatot Purwoto, Supriadi Gandamihardja, Alida R. Harahap, Primariadewi Rustamadji, Aria Kekalih, Retno Widyawati, Dzicky Rifqi Fuady
Ovarian cancer is one of the deadliest women’s cancers. There is much chemoresistance to ovarian cancer standard therapy. CD44+/CD24− have an essential role in developing chemoresistance and poor prognosis for the patients. We aimed to study CD44
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70a99cc3a0c3bf35eded0df7f4feb4c2
https://doi.org/10.21203/rs.3.rs-1459958/v2
https://doi.org/10.21203/rs.3.rs-1459958/v2
Autor:
Unedo Hence Markus, Sihombing, Andrijono, Gatot, Purwoto, Supriadi, Gandamihardja, Alida R, Harahap, Primariadewi, Rustamadji, Aria, Kekalih, Retno, Widyawati, Dzicky Rifqi, Fuady
Publikováno v:
Gynecologic oncology reports. 42
Ovarian cancer is the 8th deadliest common cancer in women around the world. Almost all ovarian cancer patients would experience chemoresistance, recurrence, and poor prognosis after cytoreductive surgery and platinum-based chemotherapy. Chemoresista
Autor:
Unedo Hence Markus Sihombing, Andrijono Andrijono, Gatot Purwoto, Supriadi Gandamihardja, Alida R. Harahap, Primariadewi Rustamadji, Aria Kekalih, Retno Widyawati, Dzicky Rifqi Fuady
Objective: Ovarian cancer is the 8th deadliest women’s cancer in the world. Almost all patients experienced chemoresistance, recurrence, and poor prognosis after cytoreductive surgery followed by platinum-based chemotherapy. Chemoresistant cancer c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6edfda7139aa6b833222d754facbb0d
https://doi.org/10.21203/rs.3.rs-1440070/v2
https://doi.org/10.21203/rs.3.rs-1440070/v2
Autor:
Unedo Hence Markus Sihombing, Andrijono Andrijono, Gatot Purwoto, Supriadi Gandamihardja, Alida R. Harahap, Primariadewi Rustamadji, Aria Kekalih, Dzicky Rifqi Fuady
Objective: Ovarian cancer is the 8th deadliest women’s cancer in the world. In 2018 there were 295.414 new cases with 184.799 deaths. In Indonesia, there are 13.310 (7,1%) ovarian cancer of 188.231 female cancer with an incidence of 9,7/100,000. Al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3adc0abb65f1ce00fbc09d0ea1049cd8
https://doi.org/10.21203/rs.3.rs-1440070/v1
https://doi.org/10.21203/rs.3.rs-1440070/v1
Autor:
Herman Susanto, Aditiyono Aditiyono Aditiyono, Ali Budi Harsono, Ardhanu Kusumanto, Supriadi Gandamihardja, Gatot Nyarumenteng Adhipurnawan Winarno
Publikováno v:
Indonesian Journal of Obstetrics & Gynecology Science. 1:40-51
Tujuan : Membandingkan penanda tumor osteopontin (OPN), cancer antigen 125 (CA125), kombinasi sebagai prediktor keganasan pada penderita tumor ovarium. Metode : Penelitian cross sectional ini dilakukan pada pasien dengan keganasan pada kista ovarium
Autor:
M. Farid Aziz, Supriadi Gandamihardja, Herri S. Sastramihardja, Firman F. Wirakusumah, Nurhalim Shahib
Publikováno v:
Majalah Kedokteran Bandung, Vol 42, Iss 4, Pp 169-174 (2010)
Cyclooxygenase-2 (COX-2) expression and selective COX-2 inhibitor such as celecoxib, which widely used as antiinflamatory drug, is known to have role in cancer by reducing proliferation and growth of tumor cells, and increasing apoptosis. The researc